Summary
Only label portions provided (IV/injection risk, REMS/distribution, and subcutaneous-only instructions). Many claims about indications, dosing timing, pharmacodynamics, side effects, and counseling cannot be verified against the supplied label excerpts, creating substantial uncertainty.
Category Scores
Accurate Statements
Sublocade is administered as a subcutaneous (under-the-skin) injection.
Label 2.1 / 2.5: “FOR SUBCUTANEOUS INJECTION ONLY. DO NOT ADMINISTER SUBLOCADE INTRAVENOUSLY, INTRAMUSCULARLY OR INTRADERMALLY.”
Sublocade is given by a healthcare professional.
Label 5.2 REMS: restricted distribution to ensure only administered by a health care provider; only dispense directly to a healthcare provider for administration by a healthcare provider.
Sublocade requires medical supervision because it is long-acting and cannot be quickly withdrawn once given.
Partially supported by REMS restricted distribution intent to ensure administration by a healthcare provider (5.2). The specific rationale about being unable to be quickly withdrawn is not supported in the provided excerpts.
There are misuse or diversion risks if medication is not handled correctly.
Supported insofar as the label excerpted REMS/distribution controls are intended to mitigate serious harm; however the specific phrasing “misuse or diversion” is not present in provided excerpts.
Unsupported Statements
Sublocade is a brand of a once-monthly injection containing buprenorphine.
Label excerpts provided do not include brand description or dosing frequency.
Sublocade is used to treat opioid use disorder (OUD).
No indication text was provided in the supplied label excerpts.
Sublocade is used for people who have already been stabilized on buprenorphine.
No label indication/eligibility criteria were provided.
Sublocade is used as part of a long-term maintenance plan.
No label indication/maintenance language provided.
Sublocade releases buprenorphine slowly over time after subcutaneous injection.
No pharmacokinetic/mechanism text provided in supplied excerpts.
Buprenorphine in Sublocade is a partial opioid agonist.
No mechanism/agonist characterization provided in supplied excerpts.
Buprenorphine helps reduce opioid cravings and withdrawal symptoms.
No efficacy/clinical effects text provided.
Buprenorphine lowers the risk of misuse compared with immediate-release opioid products.
No comparative misuse-risk language provided.
Sublocade is typically injected in the abdomen (belly).
Excerpts provided include allowed sites (abdomen, thigh, buttock, back of upper arm) but do not state “typically” or focus on abdomen specifically; supported content about site choice is insufficient to verify 'typically'.
Sublocade is a depot (long-acting) injection.
No depot/long-acting characterization provided in supplied excerpts.
Dosing is designed around once-monthly administration rather than daily dosing.
No dosing frequency guidance provided.
Many patients feel benefits ... within days ...
No onset-of-effect counseling/claims provided.
Medication levels build and then stay relatively steady between monthly doses.
No pharmacokinetic steady-state/level-trajectory information provided.
Symptom control and cravings are managed over the full dosing interval.
No efficacy over dosing interval text provided.
Common opioid-related side effects ... constipation, nausea, headache, sleepiness, and dizziness.
No adverse reaction lists provided in supplied excerpts.
Serious risks of buprenorphine include respiratory depression, especially if combined with other sedatives.
No respiratory depression warning/interaction language provided in supplied excerpts.
Sublocade can cause allergic reactions.
No hypersensitivity/allergic reaction content provided in supplied excerpts.
Breathing problems can occur if Sublocade is taken with other depressant drugs such as benzodiazepines or alcohol.
No drug interaction warning language provided in supplied excerpts.
There is a risk of overdose if buprenorphine is misused or combined unsafely.
No overdose/misuse/interaction overdose language provided in supplied excerpts.
Sublocade can cause injection-site issues such as pain, redness, or swelling.
No injection-site adverse reaction content provided in supplied excerpts.
Switching to Sublocade typically involves being stabilized on buprenorphine first, then moving to monthly injection.
No switching/induction guidance provided.
The exact timing for switching depends on the form ... and the individual’s dose history.
No conversion/switching dosing guidance provided.
If a scheduled Sublocade dose is missed, buprenorphine levels may become lower over time.
No missed-dose guidance or pharmacokinetic statements provided.
After missed doses, cravings or withdrawal symptoms may return.
No missed-dose clinical effect counseling provided.
The next Sublocade dose should be scheduled through the prescribing clinician.
No missed-dose instruction provided.
There are other buprenorphine treatment options including different long-acting formulations and other maintenance approaches.
Not addressed in provided label excerpts.
Availability of direct same-formulation equivalents to Sublocade depends on approvals and patent/exclusivity status.
No regulatory/commercial availability statement provided in label excerpts.
Sublocade is an option within medication-assisted treatment (MAT) for opioid use disorder.
No MAT terminology or indication statement provided in supplied excerpts.
Sublocade is designed for maintenance therapy.
No maintenance indication language provided.
Sublocade treatment is paired with counseling and psychosocial support where appropriate.
No counseling/psychosocial integration language provided in supplied excerpts.
Sublocade requires ongoing follow-up to monitor response, side effects, and safety.
No follow-up monitoring language provided in supplied excerpts.
Contradictions
Low
AI Statement
Sublocade is administered as a subcutaneous (under-the-skin) injection.
Label Reference
2.1 / 2.5
Important Omissions
Explicit prohibition against intravenous (IV), intramuscular (IM), and intradermal administration instructions for all relevant claims about how it is given (only some administration claims were present; the response did not explicitly state 'do not administer intravenously/intramuscularly/intradermally' in the provided claim list).
Importance:
Moderate
REMS distribution/certified pharmacy/healthcare setting requirements (the response asserted healthcare professional administration but did not mention restricted distribution via the SUBLOCADE REMS Program).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Administration route is largely consistent with supplied label excerpts (subcutaneous-only). However, numerous safety-related claims (respiratory depression, interactions with benzodiazepines/alcohol, overdose risk, injection-site reactions, allergic reactions) are not verifiable against the limited label text provided, increasing the chance of inaccurate safety counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims cannot be verified because only limited label excerpts (IV risk, subcutaneous-only instruction, and REMS/distribution) were provided.
Suggested Improvement
Limit claims to those supported by the supplied label excerpts (subcutaneous-only; do not administer IV/IM/intradermally; REMS restricted distribution ensuring healthcare-provider administration). Provide the full label text for indication, dosing/missed doses, adverse reactions, and interaction warnings to enable complete alignment auditing.